148 related articles for article (PubMed ID: 35820351)
21. Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.
Cao C; Vasilatos SN; Bhargava R; Fine JL; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2017 Jan; 36(1):133-145. PubMed ID: 27212032
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic regulation of epithelial to mesenchymal transition by the Lysine-specific demethylase LSD1/KDM1A.
Ambrosio S; Saccà CD; Majello B
Biochim Biophys Acta Gene Regul Mech; 2017 Sep; 1860(9):905-910. PubMed ID: 28720390
[TBL] [Abstract][Full Text] [Related]
23. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties.
Wang J; Lu F; Ren Q; Sun H; Xu Z; Lan R; Liu Y; Ward D; Quan J; Ye T; Zhang H
Cancer Res; 2011 Dec; 71(23):7238-49. PubMed ID: 21975933
[TBL] [Abstract][Full Text] [Related]
24. Lysine-Specific Histone Demethylase 1 Promotes Oncogenesis of the Esophageal Squamous Cell Carcinoma by Upregulating DUSP4.
Han J; Ye S; Chen J; Wang K; Jin J; Zeng Z; Xue S
Biochemistry (Mosc); 2021 Dec; 86(12):1624-1634. PubMed ID: 34937541
[TBL] [Abstract][Full Text] [Related]
25. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y
Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309
[TBL] [Abstract][Full Text] [Related]
26. The histone demethylase LSD1 is a novel oncogene and therapeutic target in oral cancer.
Wang Y; Zhu Y; Wang Q; Hu H; Li Z; Wang D; Zhang W; Qi B; Ye J; Wu H; Jiang H; Liu L; Yang J; Cheng J
Cancer Lett; 2016 Apr; 374(1):12-21. PubMed ID: 26872725
[TBL] [Abstract][Full Text] [Related]
27. Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in
Miller SA; Policastro RA; Savant SS; Sriramkumar S; Ding N; Lu X; Mohammad HP; Cao S; Kalin JH; Cole PA; Zentner GE; O'Hagan HM
Mol Cancer Res; 2020 Feb; 18(2):264-277. PubMed ID: 31704733
[TBL] [Abstract][Full Text] [Related]
28. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
[TBL] [Abstract][Full Text] [Related]
29. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
[TBL] [Abstract][Full Text] [Related]
30. A Quinquennial Review of Potent LSD1 Inhibitors Explored for the Treatment of Different Cancers, with Special Focus on SAR Studies.
Sheikh KA; Iqubal A; Alam MM; Akhter M; Khan MA; Ehtaishamul Haque S; Parvez S; Jahangir U; Amir M; Khanna S; Shaquiquzzaman M
Curr Med Chem; 2024; 31(2):152-207. PubMed ID: 36718063
[TBL] [Abstract][Full Text] [Related]
31. Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
Menna M; Fiorentino F; Marrocco B; Lucidi A; Tomassi S; Cilli D; Romanenghi M; Cassandri M; Pomella S; Pezzella M; Del Bufalo D; Zeya Ansari MS; Tomašević N; Mladenović M; Viviano M; Sbardella G; Rota R; Trisciuoglio D; Minucci S; Mattevi A; Rotili D; Mai A
Eur J Med Chem; 2022 Jul; 237():114410. PubMed ID: 35525212
[TBL] [Abstract][Full Text] [Related]
32. Annual review of LSD1/KDM1A inhibitors in 2020.
Fu DJ; Li J; Yu B
Eur J Med Chem; 2021 Mar; 214():113254. PubMed ID: 33581557
[TBL] [Abstract][Full Text] [Related]
33. Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations.
Macheleidt IF; Dalvi PS; Lim SY; Meemboor S; Meder L; Käsgen O; Müller M; Kleemann K; Wang L; Nürnberg P; Rüsseler V; Schäfer SC; Mahabir E; Büttner R; Odenthal M
Mol Oncol; 2018 Nov; 12(11):1965-1979. PubMed ID: 30220105
[TBL] [Abstract][Full Text] [Related]
34. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.
Kauffman EC; Robinson BD; Downes MJ; Powell LG; Lee MM; Scherr DS; Gudas LJ; Mongan NP
Mol Carcinog; 2011 Dec; 50(12):931-44. PubMed ID: 21400613
[TBL] [Abstract][Full Text] [Related]
35. MOF Acetylates the Histone Demethylase LSD1 to Suppress Epithelial-to-Mesenchymal Transition.
Luo H; Shenoy AK; Li X; Jin Y; Jin L; Cai Q; Tang M; Liu Y; Chen H; Reisman D; Wu L; Seto E; Qiu Y; Dou Y; Casero RA; Lu J
Cell Rep; 2016 Jun; 15(12):2665-78. PubMed ID: 27292636
[TBL] [Abstract][Full Text] [Related]
36. LPE-1, an orally active pyrimidine derivative, inhibits growth and mobility of human esophageal cancers by targeting LSD1.
Wang B; Zhao B; Pang LP; Zhao YD; Guo Q; Wang JW; Zheng YC; Zhang XH; Liu Y; Liu GY; Guo WG; Wang C; Li ZH; Mao XJ; Yu B; Ma LY; Liu HM
Pharmacol Res; 2017 Aug; 122():66-77. PubMed ID: 28571892
[TBL] [Abstract][Full Text] [Related]
37. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylation of LSD1 at Ser112 is crucial for its function in induction of EMT and metastasis in breast cancer.
Feng J; Xu G; Liu J; Zhang N; Li L; Ji J; Zhang J; Zhang L; Wang G; Wang X; Tan J; Huang B; Lu J; Zhang Y
Breast Cancer Res Treat; 2016 Oct; 159(3):443-56. PubMed ID: 27572339
[TBL] [Abstract][Full Text] [Related]
39. HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.
Cao C; Wu H; Vasilatos SN; Chandran U; Qin Y; Wan Y; Oesterreich S; Davidson NE; Huang Y
Int J Cancer; 2018 Sep; 143(6):1388-1401. PubMed ID: 29633255
[TBL] [Abstract][Full Text] [Related]
40. Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and alters gene expression of human colon cancer cells in a p53- and DNMT1(DNA methyltransferase 1)-independent manner.
Jin L; Hanigan CL; Wu Y; Wang W; Park BH; Woster PM; Casero RA
Biochem J; 2013 Jan; 449(2):459-68. PubMed ID: 23072722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
